Bioqube Ventures is a specialist life sciences investment firm. We source, finance and develop innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors.
Bioqube Ventures launched in 2020 its first independent fund “Bioqube Factory Fund I”
… an early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.
… a fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures.
… a hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.
The Bioqube Factory Fund I is supported by InnovFin Equity with the financial backing of the European Union under Horizon 2020, the Framework Programme for Research and Innovation. InnovFin Equity investments is deployed by the European Investment Fund.
Enhanc3D Genomics raises £10 million in Series A financing to advance GenLink3D proprietary technology platform
20 October, 2022
TRIDEK-ONE CLOSES A €16 MILLION FINANCING ROUND TO DEVELOP FIRST-IN-CLASS IMMUNE CHECKPOINT AGONISTS
15 September, 2022